Open Access

Long non‑coding RNA receptor activator of nuclear factor‑κ B ligand promotes cisplatin resistance in non‑small cell lung cancer cells

Retraction in: /10.3892/etm.2024.12560

  • Authors:
    • Zhongcheng Zhu
    • Xiaoyi Gong
    • Jing Li
    • Yufeng Shi
    • Mingyun Zhang
  • View Affiliations

  • Published online on: March 22, 2021     https://doi.org/10.3892/etm.2021.9949
  • Article Number: 518
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑small cell lung cancer (NSCLC) is a common malignancy associated with poor clinical outcomes and high mortality rate. The association between NSCLC development and long non‑coding RNA (lncRNA) expression remains to be elucidated. The current study investigated the role of a novel lncRNA, receptor activator of nuclear factor‑κ B ligand (RANKL), in the resistance of NSCLC to chemotherapy. RANKL expression was assessed via reverse transcription‑quantitative PCR, cell death rate was evaluated using flow cytometry and sensitivity of cisplatin (DDP)‑resistant A549/DDP cells to chemotherapy was determined using the Cell Counting Kit‑8 assay. Western blotting was performed to quantify p53 protein levels. Compared with matched A549 cells, A549/DDP cells exhibited significant upregulation of RANKL expression. Sensitivity of A549/DDP cells to DDP was restored following RANKL knockdown. A549 cells overexpressing RANKL exhibited notably impaired DDP sensitivity compared with controls. Conversely, downregulated RANKL expression triggered cell death and inhibited cell migration via p53 stimulation and phosphatidylinositol 3‑kinase/protein kinase B pathway suppression. The current findings indicate that RANKL contributes to DDP resistance in NSCLC and may represent a novel therapeutic target in this malignancy.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 21 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu Z, Gong X, Li J, Shi Y and Zhang M: Long non‑coding RNA receptor activator of nuclear factor‑κ B ligand promotes cisplatin resistance in non‑small cell lung cancer cells Retraction in /10.3892/etm.2024.12560. Exp Ther Med 21: 518, 2021.
APA
Zhu, Z., Gong, X., Li, J., Shi, Y., & Zhang, M. (2021). Long non‑coding RNA receptor activator of nuclear factor‑κ B ligand promotes cisplatin resistance in non‑small cell lung cancer cells Retraction in /10.3892/etm.2024.12560. Experimental and Therapeutic Medicine, 21, 518. https://doi.org/10.3892/etm.2021.9949
MLA
Zhu, Z., Gong, X., Li, J., Shi, Y., Zhang, M."Long non‑coding RNA receptor activator of nuclear factor‑κ B ligand promotes cisplatin resistance in non‑small cell lung cancer cells Retraction in /10.3892/etm.2024.12560". Experimental and Therapeutic Medicine 21.5 (2021): 518.
Chicago
Zhu, Z., Gong, X., Li, J., Shi, Y., Zhang, M."Long non‑coding RNA receptor activator of nuclear factor‑κ B ligand promotes cisplatin resistance in non‑small cell lung cancer cells Retraction in /10.3892/etm.2024.12560". Experimental and Therapeutic Medicine 21, no. 5 (2021): 518. https://doi.org/10.3892/etm.2021.9949